Whitehawk Therapeutics, Inc. Common Stock WHWK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $0-100% | $0-100% | $0-100% | $7.15M+33.5% | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $760K+16.6% | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $6.39M+35.8% | ||
| $17.23M+96.1% | $19.02M+32.6% | $14.35M+43.5% | $48.81M+273% | $8.79M-35.3% | ||
| $6.29M-50.9% | $5.87M-46.9% | $5.2M-27.6% | $5.94M-24.7% | $12.82M+20.7% | ||
| $23.52M+5.2% | $24.89M-5.0% | $19.55M-5.2% | $54.75M+152% | $22.36M-10.1% | ||
| -$23.52M-54.6% | -$24.89M-31.3% | -$19.55M-45.7% | -$54.75M-251% | -$15.22M+22.0% | ||
| $1.33M-98.5% | $1.64M+142% | $1.8M+108% | $2.13M+113% | $88.23M+7,115% | ||
| -$22.19M-130% | —— | —— | —— | $73.02M+559% | ||
| $0— | —— | —— | —— | $0— | ||
| -$22.19M-130% | -$23.25M-27.2% | -$17.75M-41.4% | -$52.62M-261% | $73.02M+499% | ||
| -$0.32-117% | -$0.37+45.6% | -$0.26+43.5% | -$0.76-40.7% | $1.83+369% | ||
| -$23.52M-54.8% | -$24.87M-31.6% | -$19.53M-46.1% | -$54.73M-252% | -$15.2M+21.9% | ||
| -$23.52M-54.6% | -$24.89M-31.3% | -$19.55M-45.7% | -$54.75M-251% | -$15.22M+22.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Whitehawk Therapeutics, Inc. Common Stock profitable?
- Whitehawk Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $115.8M over the trailing twelve months, a -288.3% net margin.
- What are Whitehawk Therapeutics, Inc. Common Stock's profit margins?
- Gross margin is 89.4% and operating margin is -1601.1%, with a -288.3% net margin.
- What is Whitehawk Therapeutics, Inc. Common Stock's earnings per share?
- Whitehawk Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.71.
- Where does Whitehawk Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.